AUM Biosciences is at the forefront of disrupting the drug development process in oncology, to deliver pioneering and affordable targeted drugs across a broad spectrum of cancers.
AUM is focused on developing a robust industry leading pipeline of best-in-class and first-in-class small molecule therapies, leveraging the latest in precision and digital medicine tools. Our core mandate of being biomarker driven, using innovative clinical trial designs and utilizing smart data differentiates us from other drug development companies. This enables us to identify innovative, early-stage molecules that can be rapidly progressed into successful and commercially viable drugs.
Early phase clinical & regulatory execution
De-Risked Pipeline Creation
Targeted acquisition of new high-potential candidates from academia and industry partners, with focus on small molecule therapies, through risk-sharing agreements.
Biomarker driven strategy with carefully designed drug trials during early phase, significantly de-risking later phases of clinical development.
Achieved by rationalizing our pipeline, which addresses monotherapy as well as combinatorial treatment potential.
Cancer is a major public health challenge and is the second only to cardiovascular disease as a leading cause of death across the world. Today, one in every six deaths is due to cancer, yet effective cancer treatment faces major challenges, affordability and availability being key among them.
Globally, costs associated with cancer care are higher than treatment costs for any other disease.
Cancer therapeutics has the lowest clinical trial success rate among all diseases.
Even when commercialised, a significant number of high potential cancer drugs fail to reach the populations with the greatest need, due to cost considerations.
Not marketed in many countries due to perceived lack of market potential and poor ability to navigate the local regulatory requirements.